Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1439-1447

  Warlick, Erica D ^a   O'Donnell, Paul V ^a   Borowitz, Michael ^a   Grupka, Nichon ^a   Decloe, Lauren ^a   Garrett Mayer, Elizabeth ^a   Borrello, Ivan ^a   Brodsky, Robert ^a   Fuchs, Ephraim ^a   Huff, Carol Ann ^a   Luznik, Leo ^a   Matsui, William ^a   Ambinder, Richard ^a   Jones, Richard J ^a   Douglas Smith, B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic bone marrow transplantation; GM CSF; Myelodysplastic syndrome; T cell depletion

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK FACTOR; T CELL DEPLETION;

ADULT; AGED; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 43049169868     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.12.017     Document Type: Article

References (34)

1. Aul C., Giagounidis A., and Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 73 4 (2001) 405-410
2. Sierra J., Perez W.S., Rozman C., Carreras E., Klein J.P., Rizzo J.D., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 6 (2002) 1997-2004
3. Sutton L., Chastang C., Ribaud P., Jouet J.P., Kuentz M., Attal M., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88 1 (1996) 358-365
4. Cahn J.Y., Labopin M., Schattenberg A., Reiffers J., Willemze R., Zittoun R., et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 11 3 (1997) 416-419
5. Wallen H., Gooley T.A., Deeg H.J., Pagel J.M., Press O.W., Appelbaum F.R., et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 23 15 (2005) 3439-3446
6. de Lima M., Anagnostopoulos A., Munsell M., Shahjahan M., Ueno N., Ippoliti C., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 3 (2004) 865-872
7. Scott B.L., Sandmaier B.M., Storer B., Maris M.B., Sorror M.L., Maloney D.G., et al. Myeloablative vs. nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 1 (2006) 128-135
8. Oran B., Giralt S., Saliba R., Hosing C., Popat U., Khouri I., et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13 4 (2007) 454-462
9. Martino R., Iacobelli S., Brand R., Jansen T., van Biezen A., Finke J., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 3 (2006) 836-846
10. Tauro S., Craddock C., Peggs K., Begum G., Mahendra P., Cook G., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 36 (2005) 9387-9393
11. Shimoni A., Hardan I., Shem-Tov N., Yeshurun M., Yerushalmi R., Avigdor A., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20 2 (2006) 322-328
12. Alyea E.P., Kim H.T., Ho V., Cutler C., DeAngelo D.J., Stone R., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12 10 (2006) 1047-1055
13. Matsui W.H., Gladstone D.E., Vala M.S., Barber J.P., Brodsky R.A., Smith B.D., et al. The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth Differ 13 6 (2002) 275-283
14. Smith B.D., Matsui W.H., Gladstone D.E., Karp J.E., Gore S.D., Huff C.A., et al. Differentiation therapy for poor risk myeloid malignancies: results of a dose finding study of bryostatin-1 (BRYO) + GM-CSF. Blood 106 11 (2005) 783a
15. Platzbecker U., Thiede C., Freiberg-Richter J., Helwig A., Mohr B., Prange G., et al. Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol 80 3 (2001) 144-149
16. Santos G.W., Tutschka P.J., Brookmeyer R., Saral R., Beschorner W.E., Bias W.B., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309 22 (1983) 1347-1353
17. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20 4 Suppl 4 (1993) 18-25
18. Huff C.A., Fuchs E.J., Noga S.J., O'Donnell P.V., Ambinder R.F., Diehl L., et al. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 9 5 (2003) 312-319
19. O'Donnell P.V., Jones R.J., Vogelsang G.B., Seber A., Ambinder R.F., Flinn I., et al. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplant 22 10 (1998) 947-955
20. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15 6 (1995) 825-828
21. Akpek G., Zahurak M.L., Piantadosi S., Margolis J., Doherty J., Davidson R., et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97 5 (2001) 1219-1226
22. Craddock C., Szydlo R.M., Klein J.P., Dazzi F., Olavarria E., van Rhee F., et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 96 1 (2000) 86-90
23. Kalbfleisch P. The statistical analysis of failure time data (1980), John Wiley and Sons, New York
24. Greenberg P., Cox C., Lebeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
25. Chakraverty R., and Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 110 1 (2007) 9-17
26. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64 17 (2004) 6337-6343
27. Mattijssen V., Schattenberg A., Schaap N., Preijers F., and de Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 19 8 (1997) 791-794
28. Matsui W., Smith B.D., Vala M., Beal N., Huff C.A., Diehl L.F., et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. Br J Haematol 128 6 (2005) 853-862
29. Depil S., Deconinck E., Milpied N., Sutton L., Witz F., Jouet J.P., et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant 33 5 (2004) 531-534
30. Shiobara S., Nakao S., Ueda M., Yamazaki H., Takahashi S., Asano S., et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 26 7 (2000) 769-774
31. de Witte T., Zwaan F., Hermans J., Vernant J., Kolb H., Vossen J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74 2 (1990) 151-155
32. de Witte T., Hermans J., Vossen J., Bacigalupo A., Meloni G., Jacobsen N., et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 3 (2000) 620-630
33. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87 12 (2002) 1286-1306
34. de Witte T., Suciu S., Verhoef G., Labar B., Archimbaud E., Aul C., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 8 (2001) 2326-2331